524 related articles for article (PubMed ID: 35306748)
21. [Advances in targeted and immune therapies for hepatocellular carcinoma].
Nan YM; Miao TG
Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):905-911. PubMed ID: 36299181
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
[TBL] [Abstract][Full Text] [Related]
23. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
25. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
26. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
27. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
28. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
29. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan.
Taketomi A
JMA J; 2021 Jul; 4(3):241-245. PubMed ID: 34414318
[TBL] [Abstract][Full Text] [Related]
32. The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma.
Oura K; Morishita A; Hamaya S; Fujita K; Masaki T
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769116
[TBL] [Abstract][Full Text] [Related]
33. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
35. A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma.
Shiozaki H; Furukawa K; Haruki K; Matsumoto M; Uwagawa T; Onda S; Yamahata Y; Ishizaki S; Abe K; Fujioka S; Nakaseko Y; Okamoto T; Ikegami T
Anticancer Res; 2023 Apr; 43(4):1761-1766. PubMed ID: 36974796
[TBL] [Abstract][Full Text] [Related]
36. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
[No Abstract] [Full Text] [Related]
37. [The Usefulness of RFA as a Conversion Therapy after Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma-A Case of Long-Term Survival with Multidisciplinary Treatment].
Matsumoto T; Hayashi H; Adachi Y; Kanemitsu K; Tajiri T; Yumoto S; Ogawa D; Shiraishi Y; Takematsu T; Tsukamoto M; Miyata T; Nakagawa S; Mima K; Nitta H; Baba H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1928-1930. PubMed ID: 38303255
[TBL] [Abstract][Full Text] [Related]
38. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
Front Oncol; 2022; 12():946693. PubMed ID: 36276151
[TBL] [Abstract][Full Text] [Related]
39. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
40. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.
Bai J; Huang M; Song B; Luo W; Ding R
Technol Cancer Res Treat; 2023; 22():15330338231159718. PubMed ID: 36855803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]